 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
15 July 1993 | Volume 119 Issue 2 | Pages 136-145
Objective: Reducing serum cholesterol lowers the risk for ischemic heart disease, but its effects on other vascular diseases are unknown. Published trials were reviewed to determine the effect of cholesterol-lowering interventions on fatal and nonfatal stroke.
Design: Meta-analysis of randomized, controlled trials.
Data Identification: A literature search of English-language studies examining the effect of modified diets or medications on cardiovascular end points from 1965 to 1992 using MEDLINE and a review of references of five quantitative overviews of cholesterol reduction and coronary disease.
Data Analysis: Thirteen studies met three eligibility criteria: patients randomized to intervention or control; fatal or nonfatal stroke reported separately; and end points assessed without knowledge of treatment status. Heterogeneity among studies and overall effects of treatment on fatal and nonfatal stroke were estimated using the Mantel-Haenszel-Peto method to combine independent study results. The influence of various study designs and interventions was explored using subgroup comparisons.
Results: For fatal stroke, the overall odds ratio associated with cholesterol-lowering interventions in 13 trials was 1.32 (95% CI, 0.94 to 1.86), and the odds ratio for the 10 single-intervention trials was 1.34 (CI, 0.91 to 1.96). Among eight trials reporting nonfatal events, the summary odds ratio for nonfatal stroke for treated participants compared with controls was 0.88 (CI, 0.70 to 1.11), and the odds ratio for total strokes was 0.98 (CI, 0.80 to 1.19). Among three trials using clofibrate, treatment significantly increased the risk for fatal stroke (odds ratio, 2.64; CI, 1.42 to 4.92) but not for nonfatal stroke (odds ratio, 0.87; CI, 0.61 to 1.26). Regression analysis showed no statistical association between the magnitude of cholesterol reduction and the risk for fatal stroke.
Conclusions: Lowering serum cholesterol through modified diets or medications does not reduce stroke mortality or morbidity in middle-aged men. Clofibrate appears to increase the risk for fatal strokes, but the mechanism for this effect is unknown.
Author and Article Information
From the Cardiovascular Health Research Unit and Department of Medicine, University of Washington and Harborview Medical Center, Seattle, Washington.
REVIEW
Cholesterol Reduction and the Risk for Stroke in Men
A Meta-Analysis of Randomized, Controlled Trials
Requests for Reprints: David Atkins, MD, MPH, Office of Disease Prevention and Health Promotion, Department of Health and Human Services, Switzer 2132, 330 C Street SW, Washington, DC 20201.
Acknowledgments: The authors thank Kristan Geissel and Judy Sanders for help in preparing this manuscript.
Grant Support: By a National Institutes of Health National Research Service Award (5T32PE1002).
This article has been cited by other articles:
|
|
 |
|
  N. N Henyan, D. M Riche, H. E East, and P. N Gann Impact of Statins on Risk of Stroke: A Meta-Analysis Ann. Pharmacother., December 1, 2007; 41(12): 1937 - 1945. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Versari, M. Gossl, D. Mannheim, E. Daghini, O. Galili, C. Napoli, L. O. Lerman, and A. Lerman Hypertension and Hypercholesterolemia Differentially Affect the Function and Structure of Pig Carotid Artery Hypertension, December 1, 2007; 50(6): 1063 - 1068. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. D. Waters, J. C. LaRosa, P. Barter, J.-C. Fruchart, A. M. Gotto Jr, R. Carter, A. Breazna, J. J.P. Kastelein, and S. M. Grundy Effects of High-Dose Atorvastatin on Cerebrovascular Events in Patients With Stable Coronary Disease in the TNT (Treating to New Targets) Study J. Am. Coll. Cardiol., November 7, 2006; 48(9): 1793 - 1799. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Sauvaget, J. Nagano, M. Hayashi, and M. Yamada Animal Protein, Animal Fat, and Cholesterol Intakes and Risk of Cerebral Infarction Mortality in the Adult Health Study Stroke, July 1, 2004; 35(7): 1531 - 1537. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. O'Rourke, N. Dean, N. Akhtar, and A. Shuaib Current and future concepts in stroke prevention Can. Med. Assoc. J., March 30, 2004; 170(7): 1123 - 1133. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-C. Corvol, A. Bouzamondo, M. Sirol, J.-S. Hulot, P. Sanchez, and P. Lechat Differential Effects of Lipid-Lowering Therapies on Stroke Prevention: A Meta-analysis of Randomized Trials Arch Intern Med, March 24, 2003; 163(6): 669 - 676. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-H. Lee, H.-J. Bae, B.-W. Yoon, H. Kim, D.-E. Kim, and J.-K. Roh Low Concentration of Serum Total Cholesterol Is Associated With Multifocal Signal Loss Lesions on Gradient-Echo Magnetic Resonance Imaging: Analysis of Risk Factors for Multifocal Signal Loss Lesions Stroke, December 1, 2002; 33(12): 2845 - 2849. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Gotto Jr and J. A. Farmer Reducing the Risk for Stroke in Patients With Myocardial Infarction: A Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering (MIRACL) Substudy Circulation, September 24, 2002; 106(13): 1595 - 1598. [Full Text] [PDF]
|
|
|
|
|
|
G. J. Blake, P. M. Ridker, and K. M. Kuntz Projected life-expectancy gains with statin therapy for individuals with elevated c-reactive protein levels J. Am. Coll. Cardiol., July 3, 2002; 40(1): 49 - 55. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. B. Horenstein, D. E. Smith, and L. Mosca Cholesterol Predicts Stroke Mortality in the Women's Pooling Project Stroke, July 1, 2002; 33(7): 1863 - 1868. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Kagansky, S. Levy, Y. Berner, E. Rimon, and H. Knobler Cholesterol lowering in the older population: time for reassessment? QJM, September 1, 2001; 94(9): 457 - 463. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Amarenco Hypercholesterolemia, lipid-lowering agents, and the risk for brain infarction Neurology, September 1, 2001; 57(90002): S35 - 44. [Abstract] [Full Text]
|
|
|
|
|
|
H. Iso, M. J. Stampfer, J. E. Manson, K. Rexrode, F. B. Hu, C. H. Hennekens, G. A. Colditz, F. E. Speizer, and W. C. Willett Prospective Study of Fat and Protein Intake and Risk of Intraparenchymal Hemorrhage in Women Circulation, February 13, 2001; 103(6): 856 - 863. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. P. Byington, B. R. Davis, J. F. Plehn, H. D. White, J. Baker, S. M. Cobbe, and J. Shepherd Reduction of Stroke Events With Pravastatin : The Prospective Pravastatin Pooling (PPP) Project Circulation, January 23, 2001; 103(3): 387 - 392. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. B. Goldstein, R. Adams, K. Becker, C. D. Furberg, P. B. Gorelick, G. Hademenos, M. Hill, G. Howard, V. J. Howard, B. Jacobs, et al. Primary Prevention of Ischemic Stroke : A Statement for Healthcare Professionals From the Stroke Council of the American Heart Association Circulation, January 2, 2001; 103(1): 163 - 182. [Full Text] [PDF]
|
|
|
|
|
|
L. B. Goldstein, R. Adams, K. Becker, C. D. Furberg, P. B. Gorelick, G. Hademenos, M. Hill, G. Howard, V. J. Howard, B. Jacobs, et al. Primary Prevention of Ischemic Stroke : A Statement for Healthcare Professionals From the Stroke Council of the American Heart Association Stroke, January 1, 2001; 32(1): 280 - 299. [Full Text] [PDF]
|
|
|
|
|
|
U. Laufs, K. Gertz, P. Huang, G. Nickenig, M. Bohm, U. Dirnagl, M. Endres, and C. J. Vaughan Atorvastatin Upregulates Type III Nitric Oxide Synthase in Thrombocytes, Decreases Platelet Activation, and Protects From Cerebral Ischemia in Normocholesterolemic Mice Editorial Comment Stroke, October 1, 2000; 31(10): 2442 - 2449. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J F Albucher, J Ferrieres, J B Ruidavets, B Guiraud-Chaumeil, B P Perret, and F Chollet Serum lipids in young patients with ischaemic stroke: a case-control study J. Neurol. Neurosurg. Psychiatry, July 1, 2000; 69(1): 29 - 33. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. C. Hess, A. M. Demchuk, L. M. Brass, and F. M. Yatsu HMG-CoA reductase inhibitors (statins): A promising approach to stroke prevention Neurology, February 22, 2000; 54(4): 790 - 796. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. M. Landau Is Cholesterol a Risk Factor for Stroke?: No Arch Neurol, December 1, 1999; 56(12): 1521 - 1524. [Full Text] [PDF]
|
|
|
|
|
|
S. D. Ross, I. E. Allen, J. E. Connelly, B. M. Korenblat, M. E. Smith, D. Bishop, and D. Luo Clinical Outcomes in Statin Treatment Trials: A Meta-analysis Arch Intern Med, August 9, 1999; 159(15): 1793 - 1802. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Napoli, J. L. Witztum, F. de Nigris, G. Palumbo, F. P. D'Armiento, and W. Palinski Intracranial Arteries of Human Fetuses Are More Resistant to Hypercholesterolemia-Induced Fatty Streak Formation Than Extracranial Arteries Circulation, April 20, 1999; 99(15): 2003 - 2010. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. F. Plehn, B. R. Davis, F. M. Sacks, J. L. Rouleau, M. A. Pfeffer, V. Bernstein, T. E. Cuddy, L. A. Moye, L. B. Piller, J. Rutherford, et al. Reduction of Stroke Incidence After Myocardial Infarction With Pravastatin : The Cholesterol and Recurrent Events (CARE) Study Circulation, January 19, 1999; 99(2): 216 - 223. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A Papadakis, D. P Mikhailidis, and A. F Winder Lipids and stroke: neglect of a useful preventive measure? Cardiovasc Res, November 1, 1998; 40(2): 265 - 271. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Grover, S. Paquet, C. Levinton, L. Coupal, and H. Zowall Estimating the Benefits of Modifying Risk Factors of Cardiovascular Disease: A Comparison of Primary vs Secondary Prevention Arch Intern Med, March 23, 1998; 158(6): 655 - 662. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Biller, W. M. Feinberg, J. E. Castaldo, A. D. Whittemore, R. E. Harbaugh, R. J. Dempsey, L. R. Caplan, T. F. Kresowik, D. B. Matchar, J. F. Toole, et al. Guidelines for Carotid Endarterectomy : A Statement for Healthcare Professionals From a Special Writing Group of the Stroke Council, American Heart Association Circulation, February 10, 1998; 97(5): 501 - 509. [Full Text] [PDF]
|
|
|
|
|
|
J. Biller, W. M. Feinberg, J. E. Castaldo, A. D. Whittemore, R. E. Harbaugh, R. J. Dempsey, L. R. Caplan, T. F. Kresowik, D. B. Matchar, J. F. Toole, et al. Guidelines for Carotid Endarterectomy : A Statement for Healthcare Professionals From a Special Writing Group of the Stroke Council, American Heart Association Stroke, February 1, 1998; 29(2): 554 - 562. [Full Text] [PDF]
|
|
|
|
|
|
G. Davey Smith, S. Ebrahim, J. R. Crouse III, R. P. Byington, H. M. Hoen, and C. D. Furberg Lowering of Cholesterol Levels and the Risk of Stroke Arch Intern Med, January 12, 1998; 158(1): 98 - 99. [Full Text] [PDF]
|
|
|
|
|
|
D. Tanne, S. Yaari, and U. Goldbourt High-Density Lipoprotein Cholesterol and Risk of Ischemic Stroke Mortality: A 21-Year Follow-up of 8586 Men From the Israeli Ischemic Heart Disease Study Stroke, January 1, 1997; 28(1): 83 - 87. [Abstract] [Full Text]
|
|
|
|
 |
|
 T. J. Wilt, B. R. Davis, D. G. Meyers, J.-L. Rouleau, and F. M. Sacks Prevalence and Correlates of Symptomatic Peripheral Atherosclerosis in Individuals with Coronary Heart Disease and Cholesterol Levels Less Than 240 mg/dL: Baseline Results from the Cholesterol And Recurrent Events (CARE) Study Angiology, June 1, 1996; 47(6): 533 - 541. [Abstract] [PDF]
|
|
|
|
 |
|
 A. Martinez-Riera, F. Santolaria-Fernandez, E. Gonzalez-Reimers, I. J. Perry, R.E. Gilbert, G. Jerums, M.E. Cooper, L. L. Bronner, D. S. Kanter, and J. E. Manson Primary Prevention of Stroke N. Engl. J. Med., April 25, 1996; 334(17): 1138 - 1139. [Full Text]
|
|
|
|
 |
|
 J. D. Corson, C. R. Mohan, J. J. Hoballah, W. J. Sharp, and T. F. Kresowik Atherosclerosis and Risk Factor Modification: Does It Really Make a Difference? Perspectives in Vascular Surgery and Endovascular Therapy, January 1, 1996; 9(1): 75 - 94. [PDF]
|
|
|
|
|
|
L. L. Bronner, D. S. Kanter, and J. E. Manson Primary Prevention of Stroke N. Engl. J. Med., November 23, 1995; 333(21): 1392 - 1400. [Full Text] [PDF]
|
|
|
|
|
|
A. L. Gould, J. E. Rossouw, N. C. Santanello, J. F. Heyse, and C. D. Furberg Cholesterol Reduction Yields Clinical Benefit : A New Look at Old Data Circulation, April 15, 1995; 91(8): 2274 - 2282. [Abstract] [Full Text]
|
|
Article
